Serving hundreds of leading biopharmaceutical companies globally:

Generated: October 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,623,826

« Back to Dashboard

Which drugs does patent 8,623,826 protect, and when does it expire?

Patent 8,623,826 protects AKYNZEO and is included in one NDA.

This patent has sixty-three patent family members in thirty-seven countries.

Summary for Patent: 8,623,826

Title:	Compositions and methods for treating centrally mediated nausea and vomiting
Abstract:	Provided are methods for treating nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery, comprising the co-administration of netupitant, palonosetron and dexamethasone.
Inventor(s):	Trento; Fabio (Como, IT), Cantoreggi; Sergio (Cagiallo, CH), Rossi; Giorgia (Como, IT), Cannella; Roberta (Varese, IT), Bonadeo; Daniele (Varese, IT)
Assignee:	Helsinn Healthcare S.A. (Lugano/Pazallo, CH)
Application Number:	13/077,462
Patent Claim Types: see list of patent claims	Use; Delivery;

Drugs Protected by US Patent 8,623,826

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014		RX	Yes	Yes	➤ Try a Free Trial	➤ Try a Free Trial				USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY	➤ Try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 8,623,826

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	3083	➤ Try a Free Trial
Australia	2010320598	➤ Try a Free Trial
Canada	2778301	➤ Try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army

Daiichi Sankyo

Federal Trade Commission

UBS

Queensland Health

AstraZeneca

Fish and Richardson

Medtronic

Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

if (!strstr($_SERVER['REQUEST_URI'],'/subs/')) { if (strstr($_SERVER['REQUEST_URI'],'/subscribe') || ($_SERVER['HTTP_CF_IPCOUNTRY'] != 'IN' && $_SERVER['HTTP_CF_IPCOUNTRY'] != 'CN')) { echo <<< EOF EOF; } }

By using our website you are consenting to our use of cookies in accordance with our privacy policy.